SLNO vs. RXST

In the year-to-date period, SLNO achieves a 12.47% return, which is significantly higher than RXST's -7.74% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Soleno Therapeutics, Inc. (SLNO) and RxSight, Inc. (RXST). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current SLNO Sharpe Ratio is 0.33, which is higher than the RXST Sharpe Ratio of -0.09. The chart below compares the historical Sharpe Ratios of SLNO and RXST, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither SLNO nor RXST has paid dividends to shareholders.

The maximum SLNO drawdown since its inception was -99.86%, which is greater than RXST's maximum drawdown of -48.21%. Use the drawdown chart below to compare losses from any high point for SLNO and RXST. For additional features, visit the drawdowns tool.

Soleno Therapeutics, Inc. (SLNO) and RxSight, Inc. (RXST) have volatilities of 14.42% and 13.80%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Soleno Therapeutics, Inc. and RxSight, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.